Roche Group $ROG.SW, the Swiss pharmaceutical giant, has announced plans to invest over $1.2 billion into U.S.-based manufacturing and diagnostics infrastructure as it accelerates its focus on next-generation therapies and medical technology. In a significant move that deepens the company’s operational presence in North America, Roche is committing more than $700 million to construct a state-of-the-art biologics facility in Holly Springs, North Carolina.